4 results match your criteria: "Second Hospital Affiliated to Fujian Medical University[Affiliation]"
Zhonghua Nan Ke Xue
July 2022
Department of Urology, The Second Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian 362000, China.
Objective: To investigate the correlation of the anterior lobe thickness of the prostate (ALTP) with bladder outlet obstruction (BOO), and evaluate the effect of ALTP on the clinical progression of BPH.
Methods: This retrospective study included 159 cases of BPH. We obtained the clinical indicators of the patients, including ALTP, prostate volume (PV), postvoid residual urine (PVR), maximum urinary flow rate (Qmax), BOO index (BOOI) and IPSS, and analyzed the correlations of ALTP with IPSS, PV, Qmax, age, PVR and BOOI.
J Gene Med
July 2020
Department of Pharmacy, Second Hospital Affiliated to Fujian Medical University, Quanzhou, China.
Background: Numerous abnormally expressed miRs have been reported involved in oxaliplatin (L-OHP) resistance of colorectal cancer (CRC). The present study aimed to investigate whether miR-200b-3p could regulate L-OHP resistance via targeting TUBB3 in CRC cells.
Methods: L-OHP resistant HT29 and HCT116 cells were exposed to escalating concentrations of L-OHP up to 30 μm.
Clin Interv Aging
December 2019
Departments of Geriatric, The First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, People's Republic of China.
Pharm Res
July 2018
Department of General Surgery, Affiliated Quanzhou First Hospital to Fujian Medical University, Quanzhou, Fujian, 362200, People's Republic of China.
Purpose: Immunotherapy in the clinic has demonstrated its potential to control cancer through disinhibiting the immune system, especially for immune checkpoint inhibitors such as anti-programmed cell death protein 1/anti-programmed death-ligand 1 (anti-PD1/anti-PD-L1). However, although these new immunotherapies have resulted in durable clinical responses in various cancers, multiple mechanisms of immune resistance and suppression exist in tumors. One significant barrier to efficacy of anti-PD1 against colon cancer may be the recruitment of myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment.
View Article and Find Full Text PDF